Value of infliximab (Remicade(R)) in patients with low-risk myelodysplastic syndrome: final results of a randomized phase II trial (EORTC trial 06023) of the EORTC Leukemia Group

Baron, Frédéric; Suciu, Stefan; Amadori, Sergio; Muus, Petra; Zwierzina, Heinz; Denzlinger, Claudio; Delforge, Michel; Thyss, A.; Selleslag, Dominik; Indrák, Karel; Ossenkoppele, G. J.; Witte, Théo de

doi:10.3324/haematol.2011.044347

Cited by 23 publications

(12 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 1 Cytokine targeting, particularly TNFα antagonists, is alone insufficient for MDS treatment, but some reports have sparked interest for their use in MDS-associated autoimmune disorders. 5 , 45 Recently, hypomethylating agents, such as azacitidine and decitabine, have been shown to treat MDS effectively, and several reports have shown the benefits of these agents in MDS-associated autoimmune disorders. 3 , 44 Similarly, lenalidomide has been shown to have immunomodulatory action in malignancy and to induce an increase in T-regulatory cells and a Th-17 cell imbalance; it may also be effective for the treatment of autoimmune features.…”

Section: Discussionmentioning

confidence: 99%

Inflammatory Arthritis in Patients With Myelodysplastic Syndromes

et al. 2014

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Inflammatory Arthritis in Patients With Myelodysplastic Syndromes

et al. 2014

View full text Add to dashboard Cite

show abstract

“…[62] Single agent studies of etanercept, a TNFαreceptor mimetic, and infliximab, a monoclonal antibody to TNFα, showed some early activity, however a phase II trial of infliximab reported low activity and insufficient responses. [62, 63] Combinations with anti-TNF agents have also been underwhelming. Azacitidine, a DNA methyltansferase inhibitor (DNMTi), and etanercept were combined with a reported 72% overall response rate after 3 months of therapy; however, this was a single arm study and response criteria differed from key historical controls with azacitidine alone.…”

Section: Introductionmentioning

confidence: 99%

Disordered Immune Regulation and its Therapeutic Targeting in Myelodysplastic Syndromes

Ivy

Ferrell

2018

Curr Hematol Malig Rep

View full text Add to dashboard Cite

Immune alterations in MDS are complex, heterogeneous, and intertwined with clonal hematopoiesis and stromal cell dysfunction. Inflammation in MDS proceeds as a vicious cycle, mediated in large part by secreted factors, which induce cell death and activate innate immune signaling. Therapeutic targeting of this variable immune dysregulation has led to modest responses thus far, but incorporation of the growing repertoire of immunotherapy brings new potential for improved outcomes. The immune milieu is variable across the spectrum of MDS subtypes, with a changing balance of inflammatory and suppressive cellular forces from low- to high-risk disease.

show abstract

“…Biologics are largely used for SIADs without underlying MDSs/CMML, and tumor necrosis factor α (TNF-α) antagonists were used for MDSs without increasing the risk of leukemia transformation or cytopenias (3,4). Only a few cases reported the interest of biologics in MDS-related SIADs, and large case-series in this topic are lacking (5)(6)(7).…”

Section: Accepted Manuscript Introductionmentioning

confidence: 99%